Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.58 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18593556 | 1.00 | NFE2L2 (0.58) | NFE2L2HCAR2TNFKEAP1ALDH1A1 | |
| SCHEMBL18174423 | 0.96 | NFE2L2 (0.60) | NFE2L2HCAR2TNFKEAP1ALDH1A1 | |
| SCHEMBL18174425 | 0.94 | NFE2L2 (0.65) | NFE2L2HCAR2TNFKEAP1 | |
| SCHEMBL18174428 | 0.94 | NFE2L2 (0.65) | NFE2L2HCAR2TNFKEAP1 | |
| SCHEMBL18174422 | 0.90 | NFE2L2 (0.67) | NFE2L2HCAR2TNFKEAP1KDM4E | |
| SCHEMBL18174424 | 0.90 | NFE2L2 (0.67) | NFE2L2HCAR2TNFKEAP1KDM4E | |
| SCHEMBL18174459 | 0.89 | NFE2L2 (0.58) | NFE2L2HCAR2TNFKEAP1 | |
| SCHEMBL18174454 | 0.89 | NFE2L2 (0.58) | NFE2L2HCAR2TNFKEAP1 | |
| SCHEMBL18593554 | 0.85 | NFE2L2 (0.60) | NFE2L2HCAR2TNFKEAP1 | |
| SCHEMBL18174392 | 0.83 | NFE2L2 (0.65) | NFE2L2HCAR2TNFKEAP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801866-B2 | Fumarate analogs and uses thereof | Rigl Pharmaceutical, Inc. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170065569-A1 | Fumarate Analogs and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-03-09 | — | — | US | disclosed |
| US-9475781-B2 | Fumarate analogs and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065569-A1 | Fumarate Analogs and Uses Thereof | FH, GLS, FPGS | NFE2L2 205/4885HCAR2 737/4885TNF 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.